AOR

The Archives of Ophthalmological Research aims to publish issues related to publish articles of the highest scientific and clinical value at an international level, and accepts articles on these topics. The target audience of the journal included specialists and physicians working in ophthalmology, and other health professionals interested in these fields.

EndNote Style
Index
Original Article
Dexamethasone implantation causing iatrogenic lens injury: a review of literature with case series
You can access the erratum article.
Aims: In this study, three cases of iatrogenic lens injuries during Dexamethasone (DXM) implantation will be discussed and current approaches will be reviewed with the literature.
Methods: Three patients with iatrogenic lens injury during DXM implantation were evaluated retrospectively.
Results: The three patients underwent DXM implantation for cystoid macular edema with central retinal vein occlusion and one patient for EALES disease. The surgical intervention was performed in all three patients in conjunction with cataract surgery. Intraocular lens implanted into the sulcus in all patients. The DXM could be directed to the vitreous in two patients with intact anterior hyaloid, while the other patient underwent anterior vitrectomy and DXM explanation. Anti-vascular endothelial growth factor was injected in the patient who could not implant DXM. The lens was stable in all patients in postoperative controls. There was a decrease in macular thickness at follow-up.
Conclusion: Dexamethasone implant is a slow-release tablet for macular edema due to retinal vein occlusion, diabetic retinopathy and non-infectious uveitis. Lens injury during dexamethasone implantation is a rare complication. In our series, the implant occluded the visual axis and most of it was in the lens, managed with cataract surgery. If possible, DXM should be directed to the vitreous, if not, treatment modalities should be specificized on a patient-by-patient basis.


1. Pacella F, Ferraresi AF, Turchetti P, et al. Intravitreal injection of Ozurdex (&reg;) implant in patients with persistent diabetic macular edema, with six-month follow-up. <em>Ophthalmol Eye Dis.</em> 2016;8:11-16.
2. Lowder C, Belfort Jr R, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. <em>Arch Ophthalmol.</em> 2011;129(5):545-553.
3. Schmitz K, Maier M, Clemens CR, et al. Zuverl&auml;ssigkeit und Sicherheit von intravitrealen Ozurdex-injektionen. Die ZERO-studie. <em>Ophthalmologe</em>. 2014;111(1):44-52. doi:10.1007/s00347-012-2737-2
4. Agrawal R, Fernandez-Sanz G, Bala S, et al. Desegmentation of Ozurdex implant in vitreous cavity: report of two cases. <em>Br J Ophthalmol.</em> 2014;98(7):961-963.
5. Poornachandra B, Kumar VBM, Jayadev C, et al. Immortal Ozurdex: a 10-month follow-up of an intralenticular implant. <em>Indian J Ophthalmol</em>. 2017;65(3):255-257.
6. Coca-Robinot J, Casco-Silva B, Armad Maresca F, et al. Accidental injection of dexamethasone intravitreal implant (Ozurdex) into the crystalline lens. <em>Eur J Ophthalmol.</em> 2014;24(4):633-666.
7. Regan K, Blake CR, Lukowski ZL, et al. Intralenticular Ozurdex- one year later. <em>Case Rep Ophthalmol.</em> 2017;8(3):590-594.
8. Khurana RN, Appa SN, McCannel CA, et al. Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies. <em>Ophthalmology.</em> 2014; 121(1):67-71.
9. Munteanu M, Rosca C. Repositioning and follow-up of intralenticular dexamethasone implant. <em>J Cataract Refract Surg. </em>2013;39(8):1271-1274.
10. Sekeroglu MA, Anayol MA, Koc F et al. Intralenticular sustained-release dexamethasone implant: is it still effective on macular edema. <em>Case Rep Ophthalmol.</em> 2016;7(1):85-89.
11. Costello MA, Liu J, Wang Y, et al. Reverse engineering the Ozurdex dexamethasone intravitreal implant. <em>Int J Pharm. </em>2023;634:122625.
12. Meyer CH, Rodrigues EB, Michels S, et al. Incidence of damage to the crystalline lens during intravitreal injections. <em>J Ocul Pharmacol Ther.</em> 2010;26(5):491-495.
13. Valverde-Megias A, Hernandez-Ruiz S, Cifuentes-Canorea P, et al. Intralenticular Ozurdex implant: what to do and how. <em>J Fr Ophthalmol</em>. 2018;41(4):149-150.
14. Baskan B, Cıcek A, Gulhan A, Gundogan M, Goktas S. Ozurdex completely located inside a crystallized lens-results of 14 months. <em>Am J Ophthalmol Case Rep.</em> 2016;4:38-40.
15. &Ccedil;iloğlu E, İnan P. Intralenticular dexamethasone: a case report. <em>J Retina Vitreous.</em> 2021;30(2).
16. Fasce F, Battaglia PM, Knutsson KA, et al. Accidental injection of dexamethasone intravitreal implant in the crystalline lens. <em>Acta Ophthalmol.</em> 2014;92(4):330-331.
17. Kocak N, Ozturk T, Karahan E, Kaynak S. Anterior migration of dexamethasone implant in a pseudophakic patient with intact posterior capsule. <em>Indian J Ophthalmol. </em>2014;62(11):1086-1088.
18. Srinivasan P, Jayadev C Shetty R. The nomadic Ozurdex&reg;: anterior migration of the dexamethasone implant and back!. <em>Oman J Ophthalmol. </em>2017;10(2):109-111.
19. Kumar A, Ambiya V, Kapoor G, Arora A. Wandering Ozurdex in eyes with scleral fixated intraocular lens and its management: a report of two cases.<em> J Curr Ophthalmol. </em>2019;31(3):345-348.
Volume 1, Issue 4, 2024
Page : 56-59
_Footer